COMP <GO>
LLY vs MRK // ALTMAN Z-SCORE & DEBT/EQUITY
Eli Lilly and Company (NYSE) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: LLY 9
— MRK 6
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: LLY
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.33T
balance-sheet
9.29
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
balance-sheet
5.19
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (LLY VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | LLY | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 83.64% | 74.80% | +8.84 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 32.36% | 20.70% | +11.66 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 36.4x | 15.3x | +21.12 | MRK | /valuation <GO> |
| Free Cash Flow Yield | 2.30% | 3.42% | -1.12 | MRK | /fcf-yield <GO> |
| Operating Margin | 40.21% | 34.30% | +5.91 | LLY | /operating-margins <GO> |
| Net Profit Margin | 31.90% | 28.10% | +3.80 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 45.51% | 1.30% | +44.21 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.49% | 2.26% | -1.77 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 9.29 | 5.19 | +4.10 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.77% | 6.60% | +0.17 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 77.9 | 56.9 | +21.02 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.51 | 0.92 | -0.41 | MRK | /macro-sensitivity <GO> |
| Forward P/E Multiple | 26.3x | 18.4x | +7.85 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.33T | $361.02B | $973.39B | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | LLY REV | MRK REV | LLY GROSS % | MRK GROSS % | LLY FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $65.18B | $65.01B | 83.0% | 74.8% | $16.81B | $12.36B |
| FY 2024 | $45.04B | $64.17B | 81.3% | 76.3% | $8.82B | $18.10B |
| FY 2023 | $34.12B | $60.12B | 79.3% | 44.0% | $4.24B | $10.30B |
| FY 2022 | $28.54B | — | 76.8% | — | $7.59B | — |
| FY 2021 | $28.32B | — | 74.2% | — | $7.37B | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
LLY // BETA 0.51
MRK // BETA 0.92